Health & Fitness
Health and Fitness
Health and Fitness
Fri, March 30, 2012Thu, March 29, 2012Wed, March 28, 2012Tue, March 27, 2012Mon, March 26, 2012Sun, March 25, 2012Sat, March 24, 2012Fri, March 23, 2012Thu, March 22, 2012Wed, March 21, 2012Tue, March 20, 2012Mon, March 19, 2012Oculus CEO Says Company Continues to Generate New Revenues by Partnering and Launching More FDA Cleared Products Despite Doubte
Published in Health and Fitness on Monday, March 26th 2012 at 4:09 GMT by Market Wire
March 26, 2012 07:01 ET
Oculus CEO Says Company Continues to Generate New Revenues by Partnering and Launching More FDA Cleared Products Despite Doubters
LOS ANGELES, CA--(Marketwire - Mar 26, 2012) - Hoji Alimi, founder and CEO of Oculus Innovative Sciences, Inc. (
In addition to drastically reducing its burn rate from over $18 million a year in 2008 to roughly $3 million for the first nine months of the current fiscal year, Alimi says his firm is significantly close to EBITDAS breakeven in September of 2011 with trailing revenues 2011 of $12.1 million. At this point, speculators are wondering whether Oculus is a good rebound play or whether the bears will continue to cast doubt on any bullish opportunities hinted at for the firm's banged up share price by its CEO.
Oculus designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. During their development phase, some opinion leaders in the space doubted whether the firm would ever successfully gain FDA approval for their various products, some calling Microcyn® little more than "diluted bleach."
Alimi took exception but he and his team were happy to push the tissue care product pipeline forward. Now they look back armed with seven FDA clearances; several new partnerships and preparations are underway to launch more Microcyn® based products in the dermatology and hospital wound-care markets.
Still, the doubters continue to harp on Alimi, who served as a corporate biologist for Arterial Vascular Engineering where he also designed and managed toxicology projects related to that firm's products from 1995 to 1999.
Alimi, who has never been shy about taking on his most vociferous critics, attempted to set the record straight at the recent Roth Capital Growth Conference. Speaking to BioMedReports, he answered some of the questions investors and the markets most wanted his answers to.
The full video interview with Hoji Alimi, CEO of Oculus Innovative Sciences, is now available at:
[ http://www.biomedreports.com/2012032691903/rebound-play-or-scam-oculus-innovative-sciences-ceo-speaks-up.html ]
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
[ http://biomedreports.com/fdacal.html ]
News developments and live healthcare sector updates are available constantly via Twitter at: [ http://twitter.com/BioMedReports ]
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com.
